Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Rees

Showing results (11-20 of 175) with videos related to

Pageof 18
Sort By:
Expert Opinion on Therapeutic Targets|February 21, 2023
Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular levelJohn S Gibson, David C Rees
Nature Chemistry|March 8, 2011
The rise of fragment-based drug discoveryChristopher W Murray, David C Rees
Blood|September 23, 2021
Two brothers with a novel KLF1 mutationRobin M Ireland, David C Rees
Blood Advances|December 9, 2025
A tale of 2 miceDavid C Rees, John S Gibson
Journal of Inherited Metabolic Disease|June 23, 2010
A retrospective analysis of outcome of pregnancy in patients with acute porphyriaJoanne T Marsden, David C Rees
Chemmedchem|July 25, 2008
Group efficiency: a guideline for hits-to-leads chemistryMarcel L Verdonk, David C Rees
Blood|June 30, 2018
Lipid metabolism in terminal erythropoiesisJohn S Gibson, David C Rees
Ebiomedicine|September 2, 2016
How benign is sickle cell trait?John S Gibson, David C Rees
Journal of Clinical Pathology|August 3, 2013
Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyriaJoanne T Marsden, David C Rees
British Journal of Haematology|November 30, 2011
Biomarkers in sickle cell diseaseDavid C Rees, John S Gibson
Pageof 18

Showing results (11-20 of 175) with videos related to

Sort By:
Pageof 18
Expert Opinion on Therapeutic Targets|February 21, 2023
Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular levelJohn S Gibson, David C Rees
Nature Chemistry|March 8, 2011
The rise of fragment-based drug discoveryChristopher W Murray, David C Rees
Blood|September 23, 2021
Two brothers with a novel KLF1 mutationRobin M Ireland, David C Rees
Blood Advances|December 9, 2025
A tale of 2 miceDavid C Rees, John S Gibson
Journal of Inherited Metabolic Disease|June 23, 2010
A retrospective analysis of outcome of pregnancy in patients with acute porphyriaJoanne T Marsden, David C Rees
Chemmedchem|July 25, 2008
Group efficiency: a guideline for hits-to-leads chemistryMarcel L Verdonk, David C Rees
Blood|June 30, 2018
Lipid metabolism in terminal erythropoiesisJohn S Gibson, David C Rees
Ebiomedicine|September 2, 2016
How benign is sickle cell trait?John S Gibson, David C Rees
Journal of Clinical Pathology|August 3, 2013
Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyriaJoanne T Marsden, David C Rees
British Journal of Haematology|November 30, 2011
Biomarkers in sickle cell diseaseDavid C Rees, John S Gibson
Pageof 18